- Zerenia™ Clinics UK is a specialist medical cannabis clinic in
London and another strategic
approach by Khiron to improve access to medical cannabis for
patients in the UK
- Hybrid clinic model: Zerenia™ Clinics UK is a digital clinic
(www.zereniaclinic.co.uk) and will also offer in-person
appointments with medical cannabis specialist practitioners
- The new Zerenia™ location in UK brings Khiron's total global
clinic count to 15 throughout Latin
America and Europe and
underscores its proven patient-centered approach
- The implementation of the Company's clinic strategy will
strengthen Khiron's European sales, which now account for 30% of
the Company's total medical cannabis revenues for Q3 2021
TORONTO, Nov. 3, 2021 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN) (OTCQX:
KHRNF)(Frankfurt:A2JMZC), a vertically integrated medical cannabis
leader with core operations in Latin
America and Europe, is
pleased to announce the opening of Zerenia™ Clinics UK in
London as its first International
Zerenia™ clinic in Europe. This
collectively brings the Company's total clinic count to 15
globally. Both virtual and in-person appointments can be made via
the website www.zereniaclinic.co.uk.

Khiron in the United
Kingdom
The company is pursuing a consistent
approach to improve patient access to medical cannabis and to
develop the market for medical cannabis treatments in the UK. The
opening of Zerenia™ Clinics UK by an expert team is another step in
this direction that expands Khiron's presence in Europe, where medical cannabis sales have
grown more than 6x since Q1 2021. Even though Germany will continue to dominate the European
market for medical cannabis until at least 2024, industry
consultants Prohibition Partners expect the UK medical cannabis
market to show the most significant growth of any country in
Europe by 2025.
Zerenia™ Clinics UK will build upon Khiron's presence in the UK
which started in 2019 when Khiron became a founding member and also
the exclusive Latin American supplier for Project Twenty21 which
offers a subsidized pricing model for patients in the program to
help address barriers to access in the UK market. The Company
continues to focus on medical training for healthcare professionals
after receiving full Continuing Professional Development ("CPD")
accreditation for its digital educational platform, Khiron Academy,
and brings its proprietary clinical data generated in LatAm to the
UK.
The Zerenia™ Clinic model
In the initial phase of
operations, Zerenia™ Clinics UK will focus on pain management and
will then expand its therapeutic portfolio to other areas such as
mental health, women´s health, neurology and oncology. Though
prominently located in London's
famous Chelsea district, Zerenia™ Clinics UK will initially focus
on supporting patients digitally (or via video-consultations) to
enable streamlined access to patients across the UK, many of whom
suffer from debilitating conditions. Zerenia™ Clinics UK follows
the high-quality standards of personalised cannabinoid-based
therapies and pursues precision-based medicine with the central
goal to improve patient access to cannabinoid-based therapies.
In LatAm, the proven clinic model Zerenia™ is a patient-centered
integrated care model combining traditional and complementary
medicine with a focus on treatments with medical cannabis. The 14
Zerenia™ clinics in Colombia and
Peru are known for their
evidence-based treatments and highly professional applications with
over 14,000 individual patients treated to date.
Franziska Katterbach, President Khiron Europe commented, "I am
very excited about the opening of Zerenia™ Clinics UK in
London with our very experienced
local team. This is a great milestone for Khiron and will
contribute significantly to the dynamics of developing a market for
medical cannabis in the UK. From day one, it has been our goal to
improve patient access to medical cannabis where suitable and also
create evidence for the effectiveness and tolerability of medical
cannabis; opening a UK cannabis clinic is just another logical step
to serve patient's and clinician's needs."
About Khiron Life Sciences Corp.
Khiron is a leading
vertically integrated international medical cannabis company with
core operations in Latin America
and Europe. Leveraging
wholly-owned medical health clinics and proprietary telemedicine
platforms, Khiron combines a patient-oriented approach, physician
education programs, scientific expertise, product innovation, and
agricultural infrastructure to drive prescriptions and brand
loyalty with patients worldwide. The Company has a sales presence
in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in
Mexico. The Company is led by
Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Linkedin at
https://www.linkedin.com/company/khiron-life-sciences-corp/
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/khiron-opens-first-clinic-in-europe-with-zerenia-clinics-uk-301414982.html
SOURCE Khiron Life Sciences Corp.